- Home
- LGND vs DYN Comparison
LGND vs DYN Comparison
Compare LGND & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LGND | DYN |
|---|---|---|
| Founded | 1987 | 1984 |
| Country | United States | United States |
| Employees | 68 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | LGND | DYN |
|---|---|---|
| Price | $195.24 | $17.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | ★ $245.86 | $37.00 |
| AVG Volume (30 Days) | 183.6K | ★ 2.3M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | N/A |
| Revenue Next Year | $18.28 | N/A |
| P/E Ratio | $76.27 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $93.58 | $7.01 |
| 52 Week High | $227.92 | $25.00 |
Technical Indicators
Market Signals| Indicator | LGND | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 48.22 |
| Support Level | $179.55 | $16.34 |
| Resistance Level | $207.72 | $20.08 |
| Average True Range (ATR) | 10.02 | 1.17 |
| MACD | -1.59 | 0.01 |
| Stochastic Oscillator | 3.39 | 4.41 |
Price Performance
Historical ComparisonAbout LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.